Salt Lake City, Utah-based Myriad Genetics said Tuesday that it has completed enrollment of patients in its U.S. Phase 3 clinical trial of its treatment for patients with Alzheimer's disease. Myriad said that the enrollment for Flurizan includes 1600 patients, who will be in a placebo-controlled study. The company's compound is targeted at treating Alzheimer's disease, and is based on Slective Amyloid Lowering Agents (SALAs), which the company believes provides better memory and cognition for patients.
Top NewsWednesday, August 23, 2006
Myriad Completes Phase 3 Trial Enrollment